Popular weight-loss and workout supplements on sale in hundreds of vitamin shops across the nation contain a chemical nearly identical to amphetamine, the powerful stimulant, and pose dangers to the health of those who take them, according to a new study. The Food and Drug Administration documented two years ago that nine such supplements contained the same chemical, but never made public the names of the products or the companies that made them. Neither has it recalled the products nor issued a health alert to consumers as it has done with other tainted supplements. The F.
People With Dementia Are Twice as Likely to Get Covid, Huge Study Finds
In Hookups, Inequality Still Reigns - The New York Times
How, for example, can they explain the fact that some men and women who are paralyzed and numb below the waist are able to have orgasms? And how on Earth to explain the case of the amputee who felt his orgasms centered in that missing foot? No one -- no sexologist, no neuroscientist -- really knows. For a subject with so many armchair experts, the human orgasm is remarkably mysterious. In an orgasm orchestra, the genitalia may be the instruments, but the central nervous system is the conductor.
‘A Game Changer’: Drug Brings Weight Loss in Patients With Obesity
Balancing on one leg may test the stability not just of your body but also of your marriage or other intimate relationships, according to a remarkable new study of how bodily posture may affect emotional thinking. The findings add to an emerging area of science known as embodied cognition, which studies the interconnections between our physiology and our feelings. To scientists involved in embodied cognition, those two meanings overlap in unexpected and vibrant ways. The researchers then repeated the scanning while the volunteers held warm or cold packs.
For the first time, a drug has been shown so effective against obesity that patients may dodge many of its worst consequences, including diabetes, researchers reported on Wednesday. The drug, semaglutide, made by Novo Nordisk, already is marketed as a treatment for Type 2 diabetes. In a clinical trial published in the New England Journal of Medicine, researchers at Northwestern University in Chicago tested semaglutide at a much higher dose as an anti-obesity medication. Nearly 2, participants, at centers in 16 countries, injected themselves weekly with semaglutide or a placebo for 68 weeks.